Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trialJavier Cortés, Gallardo Carlos, Carlos Gallardo et al.|The Lancet|2020Cited by 1.8k
Evolution of the Randomized Controlled Trial in Oncology Over Three DecadesChristopher M. Booth, Monika K. Krzyzanowska, David W. Cescon et al.|Journal of Clinical Oncology|2008Cited by 158
Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancerDavid B. Page, Sylvia Adams, Harry D. Bear et al.|npj Breast Cancer|2019Cited by 86